UBS Group’s Protagenic Therapeutics Warrant PTIXW Stock Holding History

UBS Group’s Portfolio PTIXW Stock Details PTIXW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-3,000	Closed	-$21	–	10726
2025 Q1	$21	Buy	3,000 +2,640	+733%	+$13	﹤0.01%	10089
2024 Q4	$1	Buy	+360	New	+$3	﹤0.01%	9862
2024 Q1	–	Sell	-100	Closed	-$1	–	9877
2023 Q4	$1	Buy	+100	New	+$2	﹤0.01%	9208
2022 Q4	–	Sell	-108	Closed	–	–	11051
2022 Q3	$0	Hold	108	–	–	﹤0.01%	10802
2022 Q2	$0	Hold	108	–	–	﹤0.01%	10793
2022 Q1	$0	Buy	+108	New	+$29	﹤0.01%	10765
2021 Q4	–	Sell	-600	Closed	–	–	10598
2021 Q3	$0	Buy	+600	New	+$316	﹤0.01%	9968

Other funds holding PTIXW

Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

UBS Group's PTIXW Position: Q2 2025 in Review

UBS Group sold out of Protagenic Therapeutics Warrant (PTIXW) in Q2 2025, closing a stake of 3,000 shares — an estimated $21 sold.

UBS Group first reported a position in PTIXW in Q3 2021 and held it in 7 quarters. The position peaked at $21 in Q1 2025. 4 funds tracked by Wall St. Rank hold PTIXW as of Q2 2025.

UBS Group reported no remaining Protagenic Therapeutics Warrant position as of Q2 2025 after selling out during the quarter.
UBS Group sold 3,000 Protagenic Therapeutics Warrant shares in Q2 2025, an estimated $21.
UBS Group first reported a position in Protagenic Therapeutics Warrant in Q3 2021 and held it in 7 quarters.
UBS Group's Protagenic Therapeutics Warrant position peaked at $21 in Q1 2025.
4 funds tracked by Wall St. Rank held Protagenic Therapeutics Warrant as of Q2 2025.

Based on UBS Group's 13F filing for Q2 2025, filed 14 Aug 2025.